We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Innovative Gel Assists Clampless Vascular Surgery

By HospiMedica International staff writers
Posted on 17 Dec 2012
A water-soluble gel that forms a temporary endovascular plug provides a simpler, atraumatic method to control bleeding during vascular surgery. More...


LeGoo is a reverse thermosensitive polymer (poloxamer 407) used to control vascular hemostasis, limiting vessel trauma and facilitating blood vessel anastomosis by minimizing dissection. Legoo is a viscous liquid at room temperature, but turns into a firm plug at body temperature, thus maintaining the cylindrical shape of the vessel, and allowing sutures to be passed directly through the gel. Once the surgical procedure is completed, LeGoo is dissolved by applying ice to the vessel or by infusing cold saline, thus restoring blood flow; once dissolved, it cannot reform into a gel because the concentration is too low, and the diluted material passes through the microcirculation and excreted in urine.

Among the clinical benefits that LeGoo provides are transient vascular occlusion; elimination of radial pressure (unlike clamps, loops, or balloons); preservation of crush fragile or calcified vessels; a superior surgical field with minimal dissection; easier suturing through the gelatinous plug; shorter occlusion and anastomosis time; and a simple technique to rapidly restore blood flow. LeGoo is a product of Pluromed (Woburn, MA, USA), and is approved by the US Food and Drug Administration (FDA) for temporary endovascular occlusion in blood vessels up to 4 mm in diameter below the neck.

“LeGoo represents a major advancement in surgical technology because of its ability to control bleeding without clamps or snares that can injure delicate blood vessels,” said William E. Cohn, MD, director of minimally invasive surgical technology at the Texas Heart Institute (Houston, USA) and a member of Pluromed’s board of directors. “This breakthrough gives surgeons a way to temporarily stop blood flow into the surgical field which is imperative for clear visualization and accurate placement of sutures. I believe this technology will be widely adopted in cardiovascular surgery and perhaps in other fields in the future.”

Poloxamer 407 is a hydrophilic nonionic surfactant consisting of a central hydrophobic block of polypropylene glycol flanked by two hydrophilic blocks of polyethylene glycol. Most of the common uses of poloxamer 407 are related to its surfactant properties. For example, it is widely used in cosmetics for dissolving oily ingredients in water. It can also be found in multipurpose contact lens cleaning solutions, where its purpose there is to help remove lipid films from the lens. It can also be found in some mouthwashes.

Related Links:

Pluromed



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.